Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Twitter Feed
-
Do you know what UCB is doing in the world of chatbots? Read what Jean Pierre shares at https://t.co/nTUueuplnF https://t.co/rLkDqLuB5S
— UCB News (@ucb_news) 26.04.2019 -
Do you think #CarbonNeutrality is possible? At UCB we believe that IT IS! We make it real through carbon reduction projects and carbon compensation mechanisms. #UCB #CarbonNeutrality https://t.co/GsMZ3tBULT
— UCB News (@ucb_news) 25.04.2019 -
We continue to advance the science of immuno-dermatology in our ongoing commitment to delivering meaningful outcomes for #psoriasis patients. Read our latest news from #SPIN2019 in Paris here: https://t.co/sGKgdXuPB5 #dermatology #media https://t.co/Hq5
— UCB News (@ucb_news) 25.04.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
